Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.HIV treatment has particular benefits for people with HIV and hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Egypt launches aggressive campaign to stamp out hepatitis C

    Egypt has the highest rate of hepatitis C in the world. Now the country has undertaken an aggressive campaign to stamp out the disease, both domestically and abroad.

    06 October 2017 | FRANCE 24
  • Hep C: An end in sight?

    Despite its prevalence, hepatitis C has long been under-prioritised by health services. But could new drugs and a new commitment from the NHS mean we may finally see this killer condition eradicated?

    05 October 2017 | Drink & Drug News
  • The Hepatitis Drug Market Is Worse Than Wall Street Realises

    Slowing hepatitis C drug sales have taken a bite out of Gilead's share price.This is a smart retreat for Merck and J&J. The HCV market is well past its peak. Both of their new therapies would have been very late; AbbVie and Gilead both had new drugs approved this year. Their best hope likely would have been to compete on price in a market that's been warring over price for a while.

    04 October 2017 | Bloomberg
  • VA models provide guidance for care of hepatitis C infection

    The U.S. Department of Veterans Affairs (VA) has developed models of care that can be used to reduce the overall burden of hepatitis C virus (HCV) infection, according to a study published online Sept. 25 in the Annals of Internal Medicine.

    28 September 2017 | Medical Xpress
  • No, there isn’t a hepatitis cure ‘for hipsters’ with a £35,000 price tag and own clothing line

    A new hepatitis C drug costing ‘just’ £2,000-a-month for 18 months (£36,000) was ‘launched’ on the web with a fancy video and young people showing off the new ‘exclusive’ drug to cure hepatitis C.

    27 September 2017 | Metro
  • Injection drug users with HCV in Scotland lack awareness of DAA efficacy

    Most people who inject drugs were not aware of currently available, highly effective hepatitis C treatments, according results of a national survey in Scotland presented at the International Symposium on Hepatitis Care in Substance Users. Researchers asked, “What are the chances of hepatitis C being cured with current treatment?” Most participants responded that the chance was low or less than 40%.

    12 September 2017 | Healio
  • AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance

    AbbVie could have charged a premium for its broader, faster cure. Its choice to go cheap will make Mavyret a huge bargain relative to Gilead's drugs for many patients. Payers will likely seize on that. The major PBMs have purposefully held off on announcing which HCV drugs they'll cover next year. Gilead will have to offer very large discounts or expect to lose market share.

    07 August 2017 | Bloomberg
  • Direct-acting antivirals successfully treating hepatitis C, says Public Health England

    Public Health England (PHE) is urging the public to get tested for hepatitis C after its latest figures revealed a fall in deaths from the disease, which it attributed to the introduction of direct-acting antiviral (DAA) therapy. PHE’s annual report, published on 28 July 2017, estimated that around 200,000 people in the UK are unknowingly living with chronic hepatitis C, but it said that “revolutionary treatments” can successfully treat the disease in the vast majority of cases, with the best results in the earlier stages of the disease.

    02 August 2017 | Pharmaceutical Journal
  • Australia leads the world in hepatitis C treatment – what's behind its success?

    The key to universal access was the Australian government’s capacity to negotiate much lower drug prices than in other high-income countries, following strong advocacy from the hepatitis C sector. For instance, Australia paid an estimated ten-fold lower price per patient treated in 2016 than did Germany.

    31 July 2017 | The Conversation AU
  • Substantial fall in Hepatitis C rates in Canberra's jail with new treatments

    Justice Minister Shane Rattenbury on Friday released new figures showing how new drugs for the virus had helped reduce the number of Hepatitis C-positive inmates from 30% of the prison population in 2010 down to just three per cent this year.

    31 July 2017 | The Canberra Times
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.